Clinical trials: Tumors, Neuroendocrine
Neuroendocrine Tumors, Progression
Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
Everolimus is approved in many countries to treat patients with advanced/metastatic well-differentiated neuroendocrine tumors (NET), providing median progression-free survival times of approximately 12 months across different…
- Conditions
- Neuroendocrine Tumors, Progression, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2
- Trial name
- EVENET (NCT06472388)
- Testing
- Everolimus 5 MG
- Where
- 2 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- AC Camargo Cancer Center
Sarcoma, Ovarian Neoplasm
Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
This is a Phase 2, non-randomised, open-label, multicentric study to investigate the efficacy and safety of pembrolizumab monotherapy in 7 cohorts of patients with specific rare cancers who have unresectable locally advanced or…
- Conditions
- Sarcoma, Ovarian Neoplasm, Central Nervous System Neoplasm, Thyroid Neoplasm
- Trial name
- AcSé (NCT03012620)
- Testing
- Pembrolizumab
- Where
- France
- Volunteers
- 334 people
- Sponsor
- UNICANCER
Melanoma
Docetaxel With or Without AZD6244 in Melanoma
This is a randomised, double-blind placebo controlled phase 2 trial. Patient will be randomly assigned 1:1 between 2 treatment arms.
- Trial name
- DOC-MEK (NCT01256359)
- Testing
- Docetaxel and AZD6244
- Where
- United Kingdom
- Volunteers
- 83 people
- Sponsor
- University of Oxford
Schwannoma, Vestibular, Neurofibromatosis 2
NF2 Natural History Consortium
OBJECTIVES: I. Define the growth rates and clinical course of NF2-related tumors in patients with neurofibromatosis type 2. Associate growth rate with physical function.
- Conditions
- Schwannoma, Vestibular, Neurofibromatosis 2, Meningioma
- Trial name
- NCT00004483
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- House Ear Institute
Melanoma
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called REGN2810, also known as cemiplimab (each individually called a "study drug" or called…
- Trial name
- NCT05352672
- Testing
- Fianlimab, Cemiplimab, Pembrolizumab
- Where
- 210 sites in United States, Argentina and 22 more
- Volunteers
- 1,546 people
- Sponsor
- Regeneron Pharmaceuticals
Melanoma
Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
This study will examine the effectiveness and side effects of an experimental vaccine to prevent recurrence of melanoma. The likelihood of melanoma returning is higher in patients who have melanoma lesions deep in the skin, in…
- Trial name
- NCT00059475
- Testing
- Glycoprotein 100 (GP100): 209-217 (210M), Interleukin-2 (IL-2), Montanide ISA 51
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Carcinoma of Lung, Neuroendocrine Carcinoma of Thymus
CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors
The study involves the enrollment of 34 patients diagnosed with advanced thymic, pulmonary and duodeno-pancreatic well-differentiated high grade neuroendocrine tumors (Ki-67 > 20%).
- Trial name
- LINEAR (NCT07429851)
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- European Institute of Oncology
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
RATIONALE: Vaccines made from DNA may make the body build an effective immune response to kill tumor cells. PURPOSE: This randomized phase I trial is studying the side effects and best dose of vaccine therapy in treating patients…
- Trial name
- NCT00104845
- Testing
- human gp100 plasmid DNA vaccine, mouse gp100 plasmid DNA vaccine
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Stage IV Skin Melanoma
Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma
This is a multi-centric translational study with biological samples collection. The aim of this study is to validate a method to detect BRAFV600 in blood samples.
- Trial name
- BRAFV600 (NCT01960634)
- Where
- 13 sites in Spain
- Volunteers
- 58 people
- Sponsor
- Grupo Español Multidisciplinar de Melanoma
Neuroendrocrine Tumors, Meningioma
Dosimetry Guided PRRT With 90Y-DOTATOC
This is a Phase 2 peptide receptor radionuclide therapy trial of 90Y-DOTATOC in patients with somatostatin receptor positive tumors.
- Conditions
- Neuroendrocrine Tumors, Meningioma, Neuroblastoma, Medulloblastoma
- Trial name
- NCT03013387
- Testing
- 90Y-DOTA-3-tyr-Octreotide, Positron Emission Tomography (PET) whole body scan, Amino Acids
- Sponsor
- Sue O'Dorisio
Melanoma
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
The purpose of this study is to assess the safety profile of vemurafenib, 960 mg, administered for 6 weeks, followed by ipilimumab monotherapy in patients with BRAF V600 mutated advanced/metastatic melanoma.
- Trial name
- NCT01673854
- Testing
- Ipilimumab, Vemurafenib
- Where
- 14 sites in United States
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Vestibular Schwannoma, Acoustic Neuroma
Auditory Nerve Test System During Vestibular Schwannoma Resection
The Auditory Nerve Test System (ANTS) is a novel device that stimulates the auditory nerve much like a cochlear implant. The purpose of this study is to demonstrate feasibility of the ANTS during translabyrinthine surgery for…
- Conditions
- Vestibular Schwannoma, Acoustic Neuroma, Sensorineural Hearing Loss, Asymmetric Sensorineural Hearing Loss
- Trial name
- ANTS (NCT04241679)
- Testing
- Auditory Nerve Test System
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Neuroendocrine Tumors
Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy Study
Patients with gastroenteropancreatic neuroendocrine tumours (NET) often die from intrahepatic disease or are excluded from liver-directed treatment because of extrahepatic disease.
- Trial name
- HEPAR_Plus (NCT02067988)
- Testing
- Holmium-166 microspheres hepatic radioembolization.
- Where
- Netherlands
- Volunteers
- 34 people
- Sponsor
- UMC Utrecht
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7
Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma
This pilot phase I trial studies the side effects and best dose of genetically modified T-cells followed by aldesleukin in treating patients with stage III-IV melanoma.
- Conditions
- Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7
- Trial name
- NCT01955460
- Testing
- Aldesleukin, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Neuroendocrine Tumors, Carcinoid Tumors
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
Participants in this study have been diagnosed with a tumor such as a carcinoid, neuroendocrine tumor, neuroblastoma, Ewing's sarcoma, or brain tumor that has cells which carry somatostatin receptors.
- Conditions
- Neuroendocrine Tumors, Carcinoid Tumors, Neuroblastoma, Medulloblastoma
- Trial name
- NCT02441062
- Testing
- 68Ga-DOTATOC PET/CT
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Sue O'Dorisio
Neuroblastoma, Rhabdomyosarcoma
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
The purpose of this study is to find the safe dose of nab-paclitaxel in children with solid tumors, and to see if it works to treat these solid tumors in children and young adults (in Phase 1 ≤ 18 years old and in Phase 2 ≤ 24…
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Ewing's Sarcoma, Ewing's Tumor
- Trial name
- NCT01962103
- Testing
- nab-paclitaxel
- Where
- 20 sites in United States, Canada and 5 more
- Volunteers
- 107 people
- Sponsor
- Celgene
Melanoma
Sample Collection From Melanoma Patients
The goal of this laboratory research study is to collect blood and tumor samples from patients with malignant melanoma. Researchers want to store these samples in a secure and confidential laboratory at M. D. Anderson.
- Trial name
- NCT00507325
- Testing
- Blood Sample, Tumor Sample
- Where
- United States
- Volunteers
- 131 people
- Sponsor
- M.D. Anderson Cancer Center
Neurofibromatosis 1, Neurofibromatosis 2
The NF Registry Sponsored by the Children's Tumor Foundation
The NF Registry is a database of patient-reported symptoms, treatments, and experiences with their neurofibromatosis disease. It is a contact registry to relay clinical trial opportunities to targeted patient subgroups, and to…
- Conditions
- Neurofibromatosis 1, Neurofibromatosis 2, Schwannomatosis, NF2-related Schwannomatosis
- Trial name
- NCT01885767
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- The Children's Tumor Foundation
Intraocular Melanoma, Melanoma (Skin)
Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00025181
- Testing
- MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Southern California
Melanoma (Skin)
Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from…
- Trial name
- NCT00118313
- Testing
- incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, sargramostim
- Where
- United States
- Sponsor
- Craig L Slingluff, Jr